Cosentyx (secukinumab) - Novartis
Cosentyx: Regulatory submission for polymyalgia rheumatica in 2026 (Novartis) - Apr 29, 2025 - Q1 2025 Results 
Filing • Immunology
https://www.novartis.com/sites/novartis_com/files/q1-2025-investor-presentation.pdf
 
Apr 29, 2025
 
 
ba43d324-85d1-40c9-81eb-478920aa999e.png